[Modification of sexual functions by antidepressants]

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Medicine

Background:

• Sexual dysfunction is a common adverse event associated with antidepressant medications.
• Accurate frequency estimation is challenging due to methodological limitations.
• Antidepressants may differ in their impact on specific sexual subfunctions based on their pharmacological profiles.

Purpose of the Study:

• To review the evidence on antidepressant-induced sexual dysfunction.
• To differentiate the effects of various antidepressants on sexual function.
• To emphasize the clinical significance of monitoring sexual side effects.

Main Methods:

• Literature review and analysis of existing studies on antidepressant-induced sexual dysfunction.
• Pharmacological profiling of different antidepressant classes.
• Examination of reported effects on libido, arousal, orgasm, and ejaculation.

Main Results:

• Selective serotonin reuptake inhibitors (SSRIs) are particularly associated with impaired orgasm and ejaculation.
• Bupropion showed no reported sexual function deterioration.
• Moclobemide, viloxazine, and trazodone demonstrated potential improvements or stimulating effects on sexual function.

Conclusions:

• The incidence of sexual adverse events with antidepressants is likely underestimated.
• Sexual dysfunction significantly impacts patient compliance and treatment adherence.
• Close monitoring of sexual health is essential during antidepressant therapy.